{"id":4633,"date":"2025-04-24T11:21:01","date_gmt":"2025-04-24T02:21:01","guid":{"rendered":"https:\/\/www.nanomrna.co.jp\/en\/?page_id=4633"},"modified":"2025-06-27T16:12:32","modified_gmt":"2025-06-27T07:12:32","slug":"group","status":"publish","type":"page","link":"https:\/\/www.nanomrna.co.jp\/en\/company\/group\/","title":{"rendered":"Corporate Profile (Subsidiary Company)"},"content":{"rendered":"<div id=\"gp01\" class=\"pagenailink\"><\/div>\n<div class=\"boxInner\">\n<h2>PrimRNA Co., Ltd.<\/h2>\n<table id=\"hyobox\" class=\"profile_hyo\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<th>Corporate Name<\/th>\n<td>PrimRNA Co., Ltd.<\/td>\n<\/tr>\n<tr>\n<th>Location<\/th>\n<td>2-5-1 Atago, Minato-ku, Tokyo<\/td>\n<\/tr>\n<tr>\n<th>Establishment<\/th>\n<td>April, 2021<\/td>\n<\/tr>\n<tr>\n<th>Director<\/th>\n<td>\n<p class=\"twocolumn sp_mb10\"><span>President and CEO<\/span><span>Daisuke Nakashima<\/span><\/p>\n<p class=\"twocolumn\"><span>Deirector<\/span><span>Kenichiro Naito<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<th>Scopes of Business<\/th>\n<td>Research, development and production of mRNA medicines.<\/td>\n<\/tr>\n<tr>\n<th>Major Shareholder<\/th>\n<td>NANO MRNA Co., Ltd. (100%)<\/td>\n<\/tr>\n<tr>\n<th>Subsidiary Company (100%)<\/th>\n<td>PrimRNA AU Pty. Ltd.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>PrimRNA Co., Ltd. Corporate Name PrimRNA Co., Ltd. Location 2-5-1 Atago, Minato-ku, Tokyo Establishment April, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":3911,"menu_order":15,"comment_status":"closed","ping_status":"closed","template":"page.php","meta":[],"acf":[],"_links":{"self":[{"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/pages\/4633"}],"collection":[{"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/comments?post=4633"}],"version-history":[{"count":2,"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/pages\/4633\/revisions"}],"predecessor-version":[{"id":4670,"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/pages\/4633\/revisions\/4670"}],"up":[{"embeddable":true,"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/pages\/3911"}],"wp:attachment":[{"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/media?parent=4633"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}